Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 E7080 in medullary or radioiodine-refractory differentiated thyroid cancer
ACTRN12609000002280Phase 2Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2008
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in Medullary Thyroid Cancer (MTC) and well-differentiated thyroid cancer (WDTC), sponsored by Eisai Co., Ltd. Primary endpoint: Objective response rate. Started Oct 2008; status: active, not recruiting.
02
Drugs
lenvatinib
03
Conditions
Medullary Thyroid Cancer (MTC)well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on ACTRN12609000002280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000002280.